CN1234351C - 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途 - Google Patents

作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途 Download PDF

Info

Publication number
CN1234351C
CN1234351C CNB018082858A CN01808285A CN1234351C CN 1234351 C CN1234351 C CN 1234351C CN B018082858 A CNB018082858 A CN B018082858A CN 01808285 A CN01808285 A CN 01808285A CN 1234351 C CN1234351 C CN 1234351C
Authority
CN
China
Prior art keywords
chemical compound
carbon atoms
ring
disease
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018082858A
Other languages
English (en)
Chinese (zh)
Other versions
CN1450894A (zh
Inventor
H·威克斯卓姆
D·迪克斯特拉
B·J·文辉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Axon Biochemicals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS, Axon Biochemicals BV filed Critical H Lundbeck AS
Publication of CN1450894A publication Critical patent/CN1450894A/zh
Application granted granted Critical
Publication of CN1234351C publication Critical patent/CN1234351C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/08—Aza-anthracenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
CNB018082858A 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途 Expired - Fee Related CN1234351C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0001438A SE0001438D0 (sv) 2000-04-18 2000-04-18 New chemical compounds and their use in therapy
SE00014381 2000-04-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2005101253198A Division CN100383126C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途

Publications (2)

Publication Number Publication Date
CN1450894A CN1450894A (zh) 2003-10-22
CN1234351C true CN1234351C (zh) 2006-01-04

Family

ID=20279367

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018082858A Expired - Fee Related CN1234351C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途
CNB2005101253198A Expired - Fee Related CN100383126C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2005101253198A Expired - Fee Related CN100383126C (zh) 2000-04-18 2001-04-17 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途

Country Status (19)

Country Link
US (4) US6683087B2 (enExample)
EP (1) EP1274411B1 (enExample)
JP (1) JP4819280B2 (enExample)
CN (2) CN1234351C (enExample)
AT (1) ATE300290T1 (enExample)
AU (2) AU2001248982B2 (enExample)
CA (1) CA2406044C (enExample)
CZ (1) CZ20023455A3 (enExample)
DE (1) DE60112269T2 (enExample)
DK (1) DK1274411T3 (enExample)
ES (1) ES2244604T3 (enExample)
HU (1) HU229794B1 (enExample)
NZ (1) NZ521860A (enExample)
PL (1) PL204661B1 (enExample)
PT (1) PT1274411E (enExample)
SE (1) SE0001438D0 (enExample)
SI (1) SI1274411T1 (enExample)
WO (1) WO2001078713A1 (enExample)
ZA (1) ZA200207919B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910623B2 (en) * 2005-07-22 2011-03-22 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
WO2007013965A2 (en) * 2005-07-22 2007-02-01 Sloan-Kettering Institute For Cancer Research Synthesis of scabronines and analogues thereof
DK1907382T3 (en) 2005-07-26 2015-08-31 Bial Portela & Ca Sa Nitrocatecholderivater comt inhibitors as
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
ES2597705T3 (es) 2007-01-31 2017-01-20 Bial - Portela & Ca., S.A. Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico
US20090124651A1 (en) 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
CA2718772C (en) 2008-03-17 2017-05-02 David Alexander Learmonth Crystal forms of 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol
TW201036949A (en) * 2009-02-27 2010-10-16 Lundbeck & Co As H Treatment of dyskinesia related disorders
PL2413912T3 (pl) 2009-04-01 2019-09-30 Bial-Portela & Ca, S.A. Preparaty farmaceutyczne zawierające pochodne nitrokatecholu oraz metody ich wytwarzania
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
US8558016B2 (en) * 2009-09-18 2013-10-15 Kabaushiki Kaisha Riverson Polyphenol derivative and method for producing the same
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PT3604299T (pt) 2011-12-13 2023-10-31 Bial Portela & Ca Sa Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
GEAP202215342A (en) 2017-11-24 2022-07-11 H Lundbeck As New catecholamine prodrugs for use in treatment of parkinson's disease
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972959A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
JP7514859B2 (ja) 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
EP3972970A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
EP4247793A1 (en) 2020-11-17 2023-09-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
CA3250415A1 (en) 2022-04-25 2023-11-02 Håkan Wikström NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2023208867A1 (en) 2022-04-25 2023-11-02 Integrative Research Laboratories Sweden Ab NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF
US20250282732A1 (en) 2022-04-25 2025-09-11 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078571A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF
WO2025078574A1 (en) 2023-10-12 2025-04-17 Integrative Research Laboratories Sweden Ab NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1179954A (fr) * 1956-02-11 1959-05-29 Rhone Poulenc Sa -1 cyclohexène-1 ones-3 nu-disubstituées, leurs dérivés et leur préparation
US3991207A (en) * 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
GB1593888A (en) 1977-12-22 1981-07-22 Wyeth John & Brother Ltd Hexahydroazepine piperidine and pyrrolidine derivatives
DE3062971D1 (en) * 1979-09-14 1983-06-09 Sandoz Ag Derivatives of tetraline, their preparation and medicaments containing these compounds
ZA805648B (en) * 1979-09-14 1982-04-28 Sandoz Ltd Tetraline derivatives, their production and pharmaceutical compositions containing them
EP0077754B1 (en) * 1981-10-16 1990-09-26 Sandoz Ag Novel pharmaceutically active 1,2,3,4,4a,5,10,10a-octahydrobenzo(g)quinoline derivatives
AU6072090A (en) * 1989-07-05 1991-02-06 Whitby Research, Inc. Substituted 2-aminotetralins
EP0641320B1 (en) 1991-04-17 2001-05-30 PHARMACIA & UPJOHN COMPANY Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists
DE4114325A1 (de) 1991-05-02 1992-11-05 Sandoz Ag Octahydrobenzo(g)chinolin, seine herstellung und verwendung
GB2260980A (en) * 1991-10-31 1993-05-05 Shell Int Research Preparation of unsaturated cyclic ketones
GB9326010D0 (en) * 1993-12-21 1994-02-23 Sandoz Ltd Improvements in or relating to organic compounds
ATE330930T1 (de) * 1997-08-07 2006-07-15 Fujimoto Brothers Co Ltd Neue ethylaminderivate
WO2000006536A1 (en) * 1998-07-28 2000-02-10 Warner-Lambert Company Hexahydro-naphthalenone oximes and hydrazones
SV2001000202A (es) * 1999-10-20 2001-10-16 Warner Lambert Co Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson

Also Published As

Publication number Publication date
NZ521860A (en) 2004-03-26
US6998405B2 (en) 2006-02-14
DE60112269T2 (de) 2006-05-24
WO2001078713A1 (en) 2001-10-25
SI1274411T1 (sl) 2005-12-31
PT1274411E (pt) 2005-11-30
CZ20023455A3 (cs) 2003-04-16
HUP0300543A2 (hu) 2003-07-28
US20040138281A1 (en) 2004-07-15
PL204661B1 (pl) 2010-01-29
PL365113A1 (en) 2004-12-27
EP1274411A1 (en) 2003-01-15
JP4819280B2 (ja) 2011-11-24
SE0001438D0 (sv) 2000-04-18
CN1450894A (zh) 2003-10-22
US20030087948A1 (en) 2003-05-08
DE60112269D1 (de) 2005-09-01
CA2406044C (en) 2009-10-27
HU229794B1 (hu) 2014-07-28
US6683087B2 (en) 2004-01-27
CN100383126C (zh) 2008-04-23
HUP0300543A3 (en) 2009-04-28
USRE42802E1 (en) 2011-10-04
ZA200207919B (en) 2003-10-02
CN1781910A (zh) 2006-06-07
AU2001248982B2 (en) 2005-12-15
DK1274411T3 (da) 2005-11-14
HK1088009A1 (en) 2006-10-27
USRE43244E1 (en) 2012-03-13
CA2406044A1 (en) 2001-10-25
AU4898201A (en) 2001-10-30
ES2244604T3 (es) 2005-12-16
EP1274411B1 (en) 2005-07-27
JP2004500426A (ja) 2004-01-08
ATE300290T1 (de) 2005-08-15

Similar Documents

Publication Publication Date Title
CN1234351C (zh) 作为儿茶酚胺前体药物的苯乙胺和稠环变体及其用途
CN1041827C (zh) 被取代的3－氨基奎宁环化合物的制备方法
CN1028024C (zh) 四唑类兴奋性氨基酸受体拮抗剂的制备方法
TWI343381B (en) Process for the production of benzopyran-2-ol derivatives
BG63945B1 (bg) Тропанови производни, тяхното получаване и приложение
CN1113436A (zh) 药物反应的增效作用
JPS6263549A (ja) フエニルエタノ−ルアミノテトラリン類、その製造法及びそれを含有する薬理組成物
CN1206010A (zh) 5H－噻唑并[3,2－a]嘧啶衍生物
AU2001248982A1 (en) Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
CA2808909A1 (en) Salts of lorcaserin with optically active acids
CN1043763C (zh) 莨菪烷衍生物及其制备方法和应用
CN1079470A (zh) [(苯并二烷，苯并呋喃或苯并吡喃)烷氨基]烷基取代胍
KR970005323B1 (ko) 치료용으로 유용한 테트랄린 유도체
CN1048014C (zh) 取代的吡咯类化合物及其制法、药物组合物和用途
CZ2000894A3 (cs) 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-olové deriváty
JPH08510222A (ja) 欝病、不安神経症およびパーキンソン病を治療するための１−アリールシクロアルキルスルフィド、スルホキシドおよびスルホン
CN1043700A (zh) 用于治疗尿失禁的化合物
US6083956A (en) Optically pure androgen mediator
CA2366820C (fr) Nouveaux derives de [(2-substitue-5 -[3-thienyl]) -benzyl]-[2- ([2-isopropoxy-5-fluoro] -phenoxy) -ethyl] -amine, leur procede de preparation et leur utilisation a titre de medicaments
CN116194431A (zh) 萜酚化合物及其用途
CN1250518C (zh) 具有抗神经缺血缺氧损伤作用的胺衍生物及其在医药学中的应用
JPS58109476A (ja) トランス−インデノ〔１，２−ｂ〕−１，４−オキサジンノ鏡像異性体
HK1088009B (en) Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
JP2010536919A (ja) ノルエピネフリン、セロトニンまたはドーパミン再取り込み阻害剤として有用な３−アザビシクロ（４．１．０）ヘプタン誘導体
HK1038017B (en) Novel 2,3,3a,4,9,9a hexahydro-8-hydroxy-1h-benz[f]indoles, a method for the production thereof, and their use as medicaments

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: LUNDBECK & CO AS H

Free format text: FORMER OWNER: AXON BIOCHEMICALS B.V.

Effective date: 20050204

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20050204

Address after: Copenhagen

Applicant after: H. Lundbeck A/S

Address before: Groningen

Applicant before: Axon Biochemicals B.V.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060104

Termination date: 20150417

EXPY Termination of patent right or utility model